José Luis
Pérez Gracia
Consultor Médico
University Hospital Heidelberg
Heidelberg, AlemaniaPublications in collaboration with researchers from University Hospital Heidelberg (1)
2022
-
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial
Journal for immunotherapy of cancer, Vol. 10, Núm. 8